Marizyme (MRZM) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 16, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-53223
Entity Registrant Name	MARIZYME, INC.
Entity Central Index Key	0001413754
Entity Tax Identification Number	82-5464863
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Heritage Drive
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Jupiter
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33458
City Area Code	(561)
Local Phone Number	935-9955
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		40,828,188

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current
Cash	$ 3,172,967	$ 4,072,339
Accounts receivable	8,650	8,650
Other receivables	20,806	41,307
Prepaid expense	469,913	257,169
Inventory	15,535	22,353
Total current assets	3,687,871	4,401,818
Non-current
Property, plant and equipment, net	12,749	12,817
Operating lease right-of-use assets, net	1,098,059	1,158,776
Intangible assets, net	52,655,899	52,866,192
Prepaid royalties, non-current	339,091	339,091
Deposits	30,000	30,000
Goodwill	7,190,656	7,190,656
Total non-current assets	61,326,454	61,597,532
Total assets	65,014,325	65,999,350
Current
Accounts payable and accrued expenses	822,556	1,596,147
Note payable	284,918	127,798
Due to related parties	271,371	1,132,634
Operating lease obligations	277,142	277,142
Total current liabilities	1,655,987	3,133,721
Non-current
Operating lease obligations, net of current portion	820,917	881,634
Note payable, net of current portion		469,252
Convertible notes	318,062	26,065
Derivative liabilities	3,821,564	2,485,346
Contingent liabilities	13,143,000	11,313,000
Total non-current liabilities	18,103,543	15,175,297
Total liabilities	19,759,530	18,309,018
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021
Common stock, par value $0.001, 75,000,000 shares authorized, issued and outstanding shares - 40,828,188 and 40,528,188 at March 31, 2022 and December 31, 2021, respectively	40,828	40,528
Additional paid-in capital	99,162,415	95,473,367
Accumulated deficit	(53,948,448)	(47,823,563)
Total stockholders’ equity	45,254,795	47,690,332
Total liabilities and stockholders’ equity	$ 65,014,325	$ 65,999,350

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	40,828,188	40,528,188
Common stock, shares outstanding	40,828,188	40,528,188

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue		$ 73,952
Operating expenses:
Professional fees (includes related party amounts of $103,200, and $Nil, respectively)	544,040	529,073
Salary expenses	915,640	884,041
Research and development	1,218,296	391,504
Stock-based compensation	716,432	367,718
Depreciation and amortization	210,361	416,595
Other general and administrative expenses	390,572	295,572
Total operating expenses	3,995,341	2,884,503
Total operating loss	(3,995,341)	(2,810,551)
Other expense
Interest and accretion expenses	(299,544)
Change in fair value of contingent liabilities	(1,830,000)
Total other expense	(2,129,544)
Net loss	$ (6,124,885)	$ (2,810,551)
Loss per share – basic and diluted	$ (0.15)	$ (0.08)
Weighted average number of shares of common stock outstanding – basic and diluted	40,628,188	35,928,188

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Professional fees related parties	$ 103,200

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 35,928	$ 82,077,334	$ (36,825,634)	$ 45,287,628
Beginning balance, shares at Dec. 31, 2020	35,928,188
Stock-based compensation expense		334,385		334,385
Net loss			(2,810,551)	(2,810,551)
Ending balance, value at Mar. 31, 2021	$ 35,928	82,411,719	(39,636,185)	42,811,462
Ending balance, shares at Mar. 31, 2021	35,928,188
Beginning balance, value at Dec. 31, 2021	$ 40,528	95,473,367	(47,823,563)	47,690,332
Beginning balance, shares at Dec. 31, 2021	40,528,188
Stock-based compensation expense		716,432		716,432
Net loss			(6,124,885)	(6,124,885)
Issuance warrants		2,969,916		2,969,916
Exercise of warrants	$ 300	2,700		3,000
Exercise of warrants, shares	300,000
Ending balance, value at Mar. 31, 2022	$ 40,828	$ 99,162,415	$ (53,948,448)	$ 45,254,795
Ending balance, shares at Mar. 31, 2022	40,828,188

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (6,124,885)	$ (2,810,551)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	210,361	416,595
Stock-based compensation	716,432	334,385
Stock-based compensation - restricted common stock		33,333
Interest and accretion on convertible notes and notes payable	299,544
Issuance of warrants for services	568,679
Change in fair value of contingent liabilities	1,830,000
Change in operating assets and liabilities:
Accounts and other receivable	20,501	4,802
Prepaid expense	(212,744)	43,290
Inventory	6,818	11,700
Accounts payable and accrued expenses	(767,187)	(98,584)
Due to related parties	(861,263)
Net cash used in operating activities	(4,313,744)	(2,065,030)
Cash flows used in investing activities:
Purchase of intangible assets		(2,775)
Net cash used in investing activities		(2,775)
Cash flows from financing activities:
Proceeds from convertible promissory notes, net of issuance cost	3,411,372
Shares issued for exercise of warrants	3,000
Net cash provided by financing activities	3,414,372
Net change in cash	(899,372)	(2,067,805)
Cash at beginning of period	4,072,339	2,902,762
Cash at end of period	3,172,967	834,957
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes
Non-cash investing and financing activities:
Derivative liabilities and debt discount issued in connection with convertible notes	1,336,218
Warrants and debt discount issued in connection with convertible notes	2,401,237
Settlement of notes payable with convertible notes	$ 326,083

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 – DESCRIPTION OF BUSINESS Maryzime, Inc. (the “Company” or “Marizyme”) is a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, the Company name was changed to GBS Enterprises Inc. and from 2010 to September 2018 the Company was in the software products and advisory services business for email and instant messaging applications. The Company divested that business between December 2016 and September 2018 and focused on the acquisition of life science technologies. On March 21, 2018, the Company’s name was changed to Marizyme, Inc., to reflect the new life sciences focus. Marizyme’s common stock is currently quoted on the OTC Markets’ QB tier under the symbol “MRZM”.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The Company’s unaudited condensed consolidated financial statements are prepared using principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $ 53,948,448 at March 31, 2022 (December 31, 2021 - $ 47,823,563 ). Additionally, the Company has working capital of $ 2,031,884 (December 31, 2021 - $ 1,268,097 ) and $ 3,172,967 (December 31, 2021 - $ 4,072,339 ) of cash on hand, which may not be sufficient to fund operations for the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Under the going concern assumption, an entity is ordinarily viewed as continuing its business for the foreseeable future with neither the intention or necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to the laws and regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business. The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully develop its intangible assets, receive an approval from the U.S. Federal and Drug Administration (the “FDA”) to extend the selling of the products into the U.S. market which will allow the Company to attain profitable operations. During the next twelve months, the Company’s foreseeable cash requirements will relate to continuous operations of its business, maintaining its good standing and making the required filings with the Securities and Exchange Commission (the “SEC”), and the payment of expenses associated with its product development. The Company may experience a cash shortfall and be required to raise additional capital. Management intends to raise additional funds by way of private or public offerings. While the Company believes in the viability of its strategy to continue to develop and expand its products and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of public or private offerings. The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries: My Health Logic Inc. (“My Health Logic” or “MHL”), Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”), (collectively – “Somah”), and Marizyme Sciences, Inc. (“Marizyme Sciences”). All intercompany transactions have been eliminated on consolidation. The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with generally accepted accounting principles in the U.S. (“U.S. GAAP”). The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2022 (the “2021 Form 10-K”). The balance sheet as of December 31, 2021 was derived from audited consolidated financial statements included in the 2021 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 1 to those consolidated financial statements. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, financial condition, cash flows and stockholders’ equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities and deferred tax valuations. Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain accounts and other receivable, accounts payable and accrued expenses, notes payable, and amounts due to related parties approximate fair value due to the short-term nature of these instruments. The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk. The contingent liabilities assumed on the acquisition of Somah in 2020 consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 %, expected volatility of 69.62 %, expected dividend of $ 0 , and expected life of 6.21 years. For the three months ended March 31, 2022, changes in these assumptions resulted in a $ 806,000 increase in fair value of these liabilities. At March 31, 2022 the fair market value of performance warrants and pediatric vouchers warrants liabilities was $ 5,158,000 . ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 %. For the three months ended March 31, 2022, changes in these assumptions resulted in a $ 1,065,000 increase in fair value of these liabilities. At March 31, 2022 the fair market value of royalty payments was $ 5,053,000 . iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6 %. For the three months ended March 31, 2022, changes in these assumptions resulted in a $ 41,000 decrease in fair value of this liability. At March 31, 2022 the fair market value of rare pediatric vouchers was $ 1,109,000 . iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 78.93 0 5 1,823,000 The derivative liabilities consist of optional and automatic conversion features and the share redemption feature attached to the convertible notes, issued pursuant to the Unit Purchase Agreement (Note 7). The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. As at March 31, 2022 and December 31, 2021, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS Fair Value Hierarchy March 31, 2022 Level 1 Level 2 Level 3 Liabilities Derivative liabilities $ $ $ 3,821,564 Contingent liabilities - - 13,143,000 Total $ - $ - $ 16,964,564 Fair Value Hierarchy December 31, 2021 Level 1 Level 2 Level 3 Liabilities Derivative liabilities $ - $ - $ 2,485,346 Contingent liabilities - - 11,313,000 Total $ - $ - $ 13,798,346 The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: RECONCILIATION OF LIABILITIES AT FAIR VALUE Derivative and Contingent Liabilities Balance at December 31, 2021 $ 13,798,346 Change in fair value of contingent liabilities 1,830,000 Derivative liabilities issued pursuant to Unit Purchase Agreement 1,336,218 Balance at March 31, 2022 $ 16,964,564 The Company did not have any derivative or contingent liabilities in the three months ended March 31, 2021. Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of Duragraft, and costs related to manufacturing Duragraft for clinical trials. The Company has entered into various research and development contracts with various organizations and other companies. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be required in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Stock-Based Compensation Stock-based compensation expense for employees and directors is recognized in the Condensed Consolidated Statements of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest. Comparative Information To conform with the current period’s financial statement presentation, the Company reclassified certain professional fees, salaries, and rent expenses related to research and development activities for the period ended March 31, 2021 into research and development expenses line item on the Condensed Consolidated Statements of Operations. Such reclassifications were not considered material and did not have any effect on the Company’s net loss for the period ended March 31, 2021.

ACQUISITION

ACQUISITION	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
ACQUISITION	NOTE 4 – ACQUISITION My Health Logic Inc. On November 1, 2021, Marizyme entered into a definitive arrangement agreement with Health Logic Interactive Inc. (“HLII”) pursuant to which the Company would acquire all of the issued and outstanding common shares of My Health Logic, a wholly owned subsidiary of HLII, in exchange for common shares of Marizyme (the “Marizyme Shares”). Marizyme is dedicated to the acceleration, development and commercialization of medical technologies that promote patient health, therefore a strategic decision was made to acquire My Health Logic, which have provided Marizyme with access to MHL’s lab-on-chip technology platform and its patient-centric, digital point-of-care diagnostic device, MATLOC 1; and allowed for further growth and development of Marizyme’s portfolio of medical products. On December 22, 2021, Marizyme received the necessary regulatory, court and stock exchange approval to complete the acquisition of MHL resulting in a total of 4,600,000 230,000 11.35 40,528,188 In accordance with ASC 805-10 the substance of a transaction constitutes a business combination as the business of My Health Logic Inc. meets the definition of a business under the standard. Accordingly, the transaction was accounted for in accordance with the acquisition method of accounting, and the assets acquired, and the liabilities assumed have been recorded at their respective estimated fair values as of the acquisition date. The purchase price was based on management’s estimate of fair value of the common shares issued. According to ASC 805 the acquirer has a year from the date of acquisition to recognize measurement period adjustments. While Marizyme does not expect the carrying amount and the fair value of identifiable assets and liabilities acquired, provided below, to change, the estimates surrounding the useful life of intangible assets acquired may differ from the initial values determined. As at March 31, 2022, those estimates remain preliminary. The change in useful life of the intangible assets will not have a material impact on the net loss for the periods ended March 31, 2022 and 2021. Additionally, the Company is in the process of finalizing the tax basis related to these intangible assets which is not final as of March 31, 2022. Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid were as follows: SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION Consideration given up Common shares $ 7,774,000 Total consideration given up $ 7,774,000 Fair value of identifiable assets acquired, and liabilities assumed Net working deficit $ (613,156 ) Property, plant, and equipment 12,500 Intangible assets 6,600,000 Goodwill 1,774,656 Total identifiable assets $ 7,774,000 As a result of the My Health Logic acquisition, we acquired its lab-on-chip technology platform, its patient-centric, digital point-of-care diagnostic device - MATLOC 1 as well as patents rights and trademarks relating to it. In addition, we acquired ownership rights to MATLOC patents issued in the European Union, Canada, and the United States. The intangible assets acquired include: ● Trade name, with estimated remaining economic life of 14 ● Software, which enables customers to track and update their test results, with economic life of 15 ● Biotechnology intangible assets related to lab-on-chip technology, with estimated remaining economic life of 17 As part of the acquisition, Marizyme assumed an aggregate of $ 468,137 in notes payable, the notes are unsecured, bear interest at a rate of 9 % per annum and mature on August 12, 2022. For the three months ended March 31, 2022, Marizyme recognized $ 6,085 of interest expense on the notes payable (March 31, 2021 - $ Nil ). The Company settled an aggregate of $ 278,678 of these notes payable as part of Unit Purchase Agreement issuances during the three months ended March 31, 2022 (Note 7). As at March 31, 2022, balance of notes payable, net of current portion was $ 204,525 (December 31, 2021 - $ 469,252 ). Goodwill is attributed to the workforce and profitability of the acquired business and is not deductible for tax purposes. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 37.5 Pro-forma revenue, net income /(loss), and earnings per share are not presented for this acquisition as they are not material.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2022
Leases
LEASES	NOTE 5 – LEASES On December 11, 2020, the Company entered into a 5.5 - year lease agreement for administrative office and laboratories, which commenced in December 2020 at a monthly rent of approximately $ 10,800 , increasing by 2.5 % annually beginning in the second year of the lease until the end of the term. Additionally, pursuant to the agreement, the Company will pay approximately $ 12,000 per month in operating expenses. As at March 31, 2022, the remaining lease term was 4.17 years. The lease had been classified as an operating lease. The assets and liabilities from the lease were recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the discount rate of 3.95 The total rent expense for the three months ended March 31, 2022 and 2021 was approximately $ 110,900 and $ 35,600 , respectively. The following table summarizes supplemental balance sheet information related to the operating lease as of March 31, 2022 and December 31, 2021. SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES March 31, December 31, 2021 Right-of-use asset $ 1,098,059 $ 1,158,776 Operating lease liabilities, current $ 277,142 $ 277,142 Operating lease liabilities, non-current 820,917 881,634 Total operating lease liabilities $ 1,098,059 $ 1,158,776 As at March 31, 2022, the maturities of the lease liabilities for the periods ending December 31 are as follows: SCHEDULE OF MATURITIES OF THE LEASE LIABILITIES 2022 207,857 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,170,233 Less: present value discount (72,174 ) Total $ 1,098,059

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 6 – INTANGIBLE ASSETS Krillase As part of the asset acquisition of ACB Holding AB, Reg. No. 559119-5762, completed on September 12, 2018, Marizyme acquired all rights, titles, and interest in the Krillase technology, a group of intangible assets worth $ 28,600,000 . Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosis. The useful lives of the intangible assets are based on the life of the patent and related technology. The patents and related technology for Krillase have not been amortized since the acquisition, as they have not yet been put into operations. The Company expects to put Krillase into operations and establish the first stream of revenue from the sale of the product in 2023. DuraGraft As part of Somahlution acquisition in 2020, Marizyme purchased $ 18,170,000 My Health Logic As part of My Health Logic acquisition (Note 4), Marizyme purchased MHL’s lab-on-chip technology platform and its patient-centric, digital point-of-care diagnostic device, MATLOC, fair valued at an aggregate amount of $ 6,600,000 SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE Intangible Assets March 31, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Krillase intangible assets $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 Patents in process 122,745 - 122,745 122,745 - 122,745 DuraGraft patent 5,256,000 (673,845 ) 4,582,155 5,256,000 (572,768 ) 4,683,232 Duragraft - Distributor relationship 308,000 (51,333 ) 256,667 308,000 (43,633 ) 264,367 Duragraft IPR&D - Cyto Protectant Life Sciences 12,606,000 - 12,606,000 12,606,000 - 12,606,000 My Health Logic - Trade name 450,000 (8,840 ) 441,160 450,000 (804 ) 449,196 My Health Logic - Biotechnology 4,600,000 (74,412 ) 4,525,588 4,600,000 (6,765 ) 4,593,235 My Health Logic - Software 1,550,000 (28,416 ) 1,521,584 1,550,000 (2,583 ) 1,547,417 Total intangibles $ 53,492,745 $ (836,846 ) $ 52,655,899 $ 53,492,745 $ (626,553 ) $ 52,866,192 SCHEDULE OF GOODWILL DuraGraft My Health Logic Total Goodwill Balance, December 31, 2020 $ - $ - $ - Additions on acquisitions 5,416,000 1,774,656 7,190,656 Impairment - - - Balance, December 31, 2021 and March 31, 2022 $ 5,416,000 $ 1,774,656 $ 7,190,656 The following changes to the Company’s intangible assets had taken place in the periods indicated: SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2020 $ 42,278,211 Acquired in Somah Transaction 4,022,271 Acquired in My Health Logic Transaction 6,600,000 Additions 2,775 Amortization expense (37,065 ) Balance, December 31, 2021 $ 52,866,192 Amortization expense (210,293 ) Balance, March 31, 2022 $ 52,655,899 Future amortizations for Duragraft and My Health Logic intangible assets for the next five years will be $ 841,172 7,121,292

CONVERTIBLE PROMISSORY NOTES AN

CONVERTIBLE PROMISSORY NOTES AND WARRANTS	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES AND WARRANTS	NOTE 7 - CONVERTIBLE PROMISSORY NOTES AND WARRANTS May 2021 Unit Purchase Agreement On May 27, 2021, Marizyme entered into a Unit Purchase Agreement to sell up to 4,000,000 2.50 Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”). In May 2021, the Company issued and sold 29,978 2.50 74,945 74,945 29,978 29,978 6,745 In July 2021, the Company issued and sold 440,000 1,100,000 1,100,000 440,000 440,000 November 2021 Amended Unit Purchase Agreement On November 29, 2021, due to a lower common stock price, the Company, with the consent of all Unit holders, amended the May 2021 Unit Agreements. By rescinding their investment, the Unit holders agreed to amend the Unit Purchase Agreement, which resulted in the following significant changes to the offering: (i) Decreased the offering price under the Unit Purchase Agreement from $ 2.50 2.25 (ii) Decreased the conversion price from $ 2.50 per share to $ 2.25 per share for all current Unit holders and all future investors. (iii) Cancelled all Class A Warrants and Class B Warrants and replaced them with Class C Warrants. On December 2, 2021, the Company issued and sold to new investors 98,889 222,500 222,500 197,778 December 2021 Unit Purchase Agreement On December 21, 2021, the Company entered into a Unit Purchase Agreement (the “December UPA”) to sell up to 9,714,286 1.75 Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company at an initial conversion price of $1.75 and, (ii) a warrant to purchase two shares of Common Stock at an initial purchase price of $2.25 per share (the new Class C Warrant). 3,438,572 1.75 6,000,000 December 2021 Exchange Agreements On December 21, 2021, in conjunction with a $ 6.0 (i) Decreased the offering price under the Unit Purchase Agreement from $ 2.25 1.75 (ii) Extended the maturity date of the notes to December 21, 2023 (iii) Decreased the conversion price from $ 2.25 1.75 (iv) Original Class C Warrants were exchanged for New Class C warrants with an exercise price of $ 2.25 200 The Company determined that the terms of the New Securities were substantially different from the Original Securities, and, as such the exchange of the Original Securities for the New Securities was accounted for as an extinguishment of debt on December 21, 2021, and the New Securities accounted for as a new debt issuance. As a result of this substantial modification, the total of 621,087 832,022 During the three months ended March 31, 2022, the Company issued additional 2,290,659 4,008,653 2,290,659 159,245 22,857 171,428 The Company determined that the optional and automatic conversion feature and the share redemption feature attached to the convertible notes meet the definition of derivative liabilities and that the detachable warrants issued do not meet the definition of a liability and therefore will be accounted for as an equity instrument. The fair value of the warrants issued in the three months ended March 31, 2022, of $ 2,401,237 4,299,649 1,336,218 2,485,346 During the three months ended March 31, 2022, the Company recognized interest and accretion expense of $ 291,997 Nil SCHEDULE OF CONVERTIBLE NOTES Convertible Notes, Net of Debt Discount Balance, December 31, 2021 $ 26,065 Convertible notes issued - new securities 4,008,653 Issuance costs (271,198 ) Debt discount (3,737,455 ) Debt accretion 291,997 Balance, March 31, 2022 $ 318,062 As of March 31, 2022 and December 31, 2021, the Company had the following convertible notes, net of debt discount outstanding: SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT March 31, 2022 December 31, 2021 Convertible notes - total principal $ 11,464,692 $ 7,482,104 Unamortized issuance costs and discount (11,146,630 ) (7,456,039 ) Convertible notes, net of debt discount $ 318,062 $ 26,065 Convertible Notes Terms The Convertible Notes mature in 24 months from the initial closing date and accrue 10% of simple interest per annum on the outstanding principal amount. The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $1.75 per share (previously $2.25 per the September 2021 Amendment and originally $2.50 per the May Unit Purchase Agreement). The Convertible Notes issued or reissued in exchanged for the cancellation of previously-issued Convertible Notes from May 2021 until March 24, 2022 provide that in the event the Company consummates a qualified financing of at least $ 10 75% 60 20 6.00 1,000,000 20 In addition, the Convertible Notes provide that more favorable terms under subsequent equity issuances will become part of the Convertible Notes. The Convertible Notes also include certain customary antidilution provisions and registration rights under a Registration Rights Agreement with the investors. The Convertible Notes in our March 24, 2022 and subsequent closings were also modified to provide that upon the occurrence of certain qualified financings of $ 10 75% The conversion provision was also modified to remove the requirement that an effective registration statement allow for the issuance or resale of shares of common stock into which the convertible notes may be converted in order for the conversion price of the Convertible Notes to be subject to the reduction to 75% of the price per equity security in a qualified financing. The Convertible Notes are secured by a first priority security interest in all assets of the Company. They also have certain registration requirements for the shares of common stock underlying the Convertible Notes upon the final closing under the unit purchase agreement between the Company and the investors in this private placement. New Class C Warrants Terms ● Exercise price is the lower of (i) $ 2.25 per share, or (ii) the Automatic Conversion Price (the lesser of (i) 75 % of the cash price per share paid by the other purchasers of next round securities in a Qualified Financing and (ii) the Conversion Price ($ 2.25 , subject to Customary Antidilution Adjustments). ● Exercisable for a period of 5 ● Warrant Coverage: 200

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY a) Preferred stock The Company is authorized to issue a total number of 25,000,000 0.001 no b) Common stock The Company is authorized to issue a total number of 75,000,000 0.001 As of March 31, 2022 and December 31, 2021, there were 40,828,188 40,528,188 300,000 c) Options On May 18, 2021, our Board of Directors approved the Marizyme, Inc. Amended and Restated 2021 Stock Incentive Plan (“SIP”), and our shareholders ratified it on September 20, 2021. The SIP incorporates stock options issued prior to May 18, 2021. The SIP authorized 5,300,000 options for issuance. As of March 31, 2022, there remains 1,274,057 options available for issuance (December 31, 2021 – 1,274,057 ). During the three months ended March 31, 2022, the company granted Nil (December 31, 2021 – 1,532,500 ) share purchase options to directors, officers, employees, and consultants of the Company. The summary of option activity for the three months ended March 31, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of Options Weighted Average Exercise Price Weighted Average Contractual Life Total Intrinsic Value Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 Granted 1,532,500 1.51 Forfeited (1,682,500 ) 1.36 Outstanding at December 31, 2021 3,650,943 $ 1.24 8.34 $ 1,951,117 Granted/forfeited - - Outstanding at March 31, 2022 3,650,943 1.24 8.10 2,571,777 Exercisable at March 31, 2022 2,561,023 $ 1.10 7.56 $ 2,160,932 As of March 31, 2022, the Company had the following options outstanding: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number of Options Outstanding Number of Options Exercisable Weighted Average Remaining Contractual Years Intrinsic Value $ 1.01 1,985,943 1,985,943 7.18 $ 1,846,927 1.25 665,000 265,080 8.85 458,850 1.37 200,000 190,000 8.39 114,000 1.75 800,000 120,000 9.66 152,000 $ 1.24 3,650,943 2,561,023 8.10 $ 2,571,777 d) Restricted Share Units As of March 31, 2022, we determined that the following performance condition attached to the restricted share awards granted in the fiscal 2021 were more likely than not to be achieved: ● The Company will raise financing for the gross proceeds that equal or exceed $ 5,000,000 ● The Company will complete valuation reports for acquisition of Somahlution and My Health Logic. Therefore, compensation cost of $ 295,750 for the restricted share awards was recognized in stock-based compensation the period ended March 31, 2022 (March 31, 2021 - $ Nil ). e) Warrants As of March 31, 2022 and December 31, 2021, there are 16,726,157 and 12,144,838 warrants outstanding, respectively. SCHEDULE OF WARRANTS OUTSTANDING Number Weighted Average Price December 31, 2020 3,393,651 $ 2.13 Issued pursuant to Unit Purchase Agreement 8,521,187 2.25 Issued 230,000 1.39 December 31, 2021 12,144,838 $ 2.20 Issued pursuant to Unit Purchase Agreement 4,581,319 2.25 Issued 300,000 0.01 Exercised (300,000 ) 0.01 March 31, 2022 16,726,157 $ 2.21 During the three months ended March 31, 2022, the Company issued the following: On January 26 and February 14, 2022, in exchange for services of Mr. Richmond, we granted him 300,000 300,000 0.01 5 568,677 300,000 On January 14, January 24 and March 24, 2022 pursuant to the Unit Purchase Agreement the Company issued an aggregate of 4,581,319 2.25 five years f) Stock-based compensation During the three months ended March 31, 2022, the Company recorded $ 716,432 in non-cash share-based compensation (March 31, 2021 - $ 367,718 ).

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS As at March 31, 2022, the Company owed an aggregate of $ 271,371 1,132,634 ● The Company received consulting services from Mr. Maresca and pursuant to the agreement incurred $ 60,000 Nil 271,371 In the three months ended March 31, 2022, the Company incurred and settled additional $ 43,200 96,744 Additionally, as part of the Somah acquisition in 2020, the Company recorded a prepaid royalty to the shareholders of Somahlution. The primary beneficial owner is Dr. Vithal Dhaduk, currently a director, and significant shareholder of the Company. As at March 31, 2022, the company had $ 339,091 in prepaid royalties (December 31, 2021 - $ 339,091 ) which had been classified as non-current in the condensed consolidated balance sheets.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 – COMMITMENTS AND CONTINGENCIES Legal Matters On August 19, 2021, Dr. Neil Campbell, former President, Chief Executive Officer and director of the Company, and Bruce Harmon, former Chief Financial Officer and Secretary of the Company, each filed a Complaint and Demand for Jury Trial against the Company and Insperity Peo Services, L.P., a Delaware limited partnership (“Insperity”), a joint employer of Dr. Campbell and Mr. Harmon with the Company under a Client Service Agreement, dated November 30, 2020 (collectively, the “Campbell/Harmon Complaints”). Both Campbell/Harmon Complaints allege that the Company and Insperity violated Section 448.105 of the Florida Private Whistleblower Act as a result of the constructive terminations of Dr. Campbell and Mr. Harmon after the occurrence of violations federal and state law, including federal securities law, at the Company that exposed Dr. Campbell and Mr. Harmon to civil and criminal forms of liability and that the Company was not addressing to their satisfaction. Both Campbell/Harmon Complaints demand approximately $ 30,000 50,000 On January 28, 2022, we filed a Complaint in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida (the “Florida Circuit Court”), case number 50-2022-CA-000859-XXX-MB, against Amy Chandler (the “Chandler Complaint”). The Chandler Complaint seeks damages for breach of fiduciary duty, breach of contract, negligence, conversion, and civil theft. The Chandler Complaint alleged that, approximately two months before her resignation in September 2021, Ms. Chandler intentionally and recklessly took affirmative actions to cancel the CE certificate required by European Union regulations in order for Marizyme and its subsidiary, Somahlution, LLC, to ship and distribute certain products to/within the European Union, and disregarded her fiduciary duty to Marizyme and responsibilities as its former Executive Vice President for Regulatory Affairs and Quality Management Systems. As a result, the Chandler Complaint alleged that Ms. Chandler’s actions caused significant disruption and damage to Marizyme’s business, including, but not limited to, financial damages and damage to Marizyme’s reputation and business relationships. The Chandler Complaint further alleged that prior to her last day, Ms. Chandler stole confidential, proprietary files governing Marizyme’s quality management system, which were required for essential internal business operations, and that Marizyme incurred significant costs to recreate these files. The Chandler Complaint alleged damages in excess of thirty thousand dollars ($ 30,000.00 On February 28, 2022, Ms. Chandler filed a Answer, Affirmative Defenses and Counterclaim to Plaintiff’s Complaint with the Florida Circuit Court (the “Chandler Countercomplaint”). The Chandler Countercomplaint denied the claims in the Chandler Complaint and most of the factual allegations regarding her alleged actions. The Chandler Countercomplaint also included a counterclaim of defamation per se against the Company based on certain statements regarding this litigation that were included in the Registration Statement. As to the claims in the Chandler Complaint, the Chandler Countercomplaint demanded an award of attorneys’ fees and costs, court costs on all counts, and such further relief the court deems just and proper. As to the counterclaim of defamation, the Chandler Countercomplaint requested monetary damages, punitive damages, court costs, and any other relief the court deems just and proper. The Chandler Countercomplaint also demanded trial by jury on all triable issues. On March 18, 2022, the Company filed a Motion to Dismiss Counterclaim with the Florida Circuit Court (the “Motion to Dismiss”). The Motion to Dismiss stated that the Chandler Countercomplaint for defamation per se should be dismissed with prejudice because the Company has not made any statements about Chandler outside the allegations in the Chandler Complaint. The Motion to Dismiss stated that the statements regarding this litigation that were included in the Registration Statement were as a matter of law not false because they all accurately reproduced the allegations in the Chandler Complaint and such statements were prefaced by the words “The Chandler Complaint alleged”. The Motion to Dismiss further stated that allegations in the litigation are subject to Florida’s litigation privilege and cannot serve as a basis for a defamation claim as a matter of law. As of [*], 2022, this case was pending. Contingencies a. On July 13, 2019, the Company signed a consulting agreement, whereby the individual will receive: ● $ 30,000 ● Option to purchase 250,000 1.50 ● Royalties based on sales of Krillase assets, equal to 10 b. As part of the DuraGraft Acquisition, completed on July 31, 2020, the Company entered into the Agreement with Somah stockholders, whereby Marizyme is legally obligated to pay royalties on all net sales for Somahlution, Inc. The royalties associated with the Agreement are calculated as follows: Royalties on U.S. sales equal to: ● 5 ● 4 ● 2 Royalties on sales outside of the U.S.: ● 6 ● 4 ● 2 The royalties are in perpetuity. During the three months ended March 31, 2022, the Company had not earned any revenues from Krillase and did not have any sales of the DuraGraft products in U.S., therefore no royalties have been accrued or paid in the period. Upon receiving FDA approval for the Duragraft product, the Company will: ● Issue performance warrants with a strike price determined based on the average of the closing prices of the Company’s common stock for the 30 calendar days following the date of the public announcement of the FDA approval; and ● Upon liquidation of all or substantially all of the assets relating to DuraGraft, the Company will pay 15 20 c. The Company has entered into arrangements for office and laboratories spaces. As at March 31, 2022, minimum lease payments in relation to lease commitments are payable as described in Note 5. Risks and Uncertainties Starting in late 2019, a novel strain of the coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United States. At this time, there continues to be significant volatility and uncertainty relating to the full extent to which the COVID-19 pandemic and the various responses to it will impact our business, operations and financial results. Most states and cities have at various times instituted quarantines, restrictions on travel, “stay at home” rules, social distancing measures and restrictions on the types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. As a result, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe, which could result in delays of reviews and approvals. While there have been no specific notices of delay from federal or foreign government authorities, potential interruptions, delays, or changes to the operations of the FDA, or of any foreign authority with which we might interact, might impact the approval of any applications we plan and will need to file in the future. In addition, we are dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill our orders is critical to our business success. The COVID-19 pandemic has impacted and may continue to impact certain of our manufacturers and suppliers. As a result, we have faced and may continue to face delays or difficulty sourcing certain products, which could negatively affect our business and financial results. The spread of COVID-19 has also adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The pandemic has resulted, and may continue to result, in a significant disruption of global financial markets, which may reduce our ability to access capital in the future, which could negatively affect our liquidity. If the COVID-19 pandemic does not continue to slow and the spread of COVID-19 is not contained, our business operations, including those of contract manufacturers, could be further delayed or interrupted. The duration of any business disruption cannot be reasonably estimated at this time but may materially affect our ability to operate our business and result in additional costs. It is not possible to reliably measure or quantify the impact COVID-19 has had on the financial results of the Company. If the COVID-19 pandemic continues for an extended period, it may materially adversely impact business operations and, consequently, future financial results.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 - SUBSEQUENT EVENTS Effective April 1, 2022 the Company has amended their lease agreement for administrative office and laboratories currently leased to add additional space. The monthly cost of additional space is approximately $ 4,510 8,682 2.5 Effective May 1, 2022, the Company has leased additional laboratory space. The term of the lease is for 4.3 July 30, 2026 3,757 6 3,344 On May 11, 2022, the Company issued and sold to new investors 746,563 1,306,485 1,306,485 1,493,126

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries: My Health Logic Inc. (“My Health Logic” or “MHL”), Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”), (collectively – “Somah”), and Marizyme Sciences, Inc. (“Marizyme Sciences”). All intercompany transactions have been eliminated on consolidation. The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with generally accepted accounting principles in the U.S. (“U.S. GAAP”). The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2022 (the “2021 Form 10-K”). The balance sheet as of December 31, 2021 was derived from audited consolidated financial statements included in the 2021 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 1 to those consolidated financial statements. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, financial condition, cash flows and stockholders’ equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities and deferred tax valuations.
Fair Value Measurements	Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain accounts and other receivable, accounts payable and accrued expenses, notes payable, and amounts due to related parties approximate fair value due to the short-term nature of these instruments. The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk. The contingent liabilities assumed on the acquisition of Somah in 2020 consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 %, expected volatility of 69.62 %, expected dividend of $ 0 , and expected life of 6.21 years. For the three months ended March 31, 2022, changes in these assumptions resulted in a $ 806,000 increase in fair value of these liabilities. At March 31, 2022 the fair market value of performance warrants and pediatric vouchers warrants liabilities was $ 5,158,000 . ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 %. For the three months ended March 31, 2022, changes in these assumptions resulted in a $ 1,065,000 increase in fair value of these liabilities. At March 31, 2022 the fair market value of royalty payments was $ 5,053,000 . iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6 %. For the three months ended March 31, 2022, changes in these assumptions resulted in a $ 41,000 decrease in fair value of this liability. At March 31, 2022 the fair market value of rare pediatric vouchers was $ 1,109,000 . iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 78.93 0 5 1,823,000 The derivative liabilities consist of optional and automatic conversion features and the share redemption feature attached to the convertible notes, issued pursuant to the Unit Purchase Agreement (Note 7). The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. As at March 31, 2022 and December 31, 2021, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS Fair Value Hierarchy March 31, 2022 Level 1 Level 2 Level 3 Liabilities Derivative liabilities $ $ $ 3,821,564 Contingent liabilities - - 13,143,000 Total $ - $ - $ 16,964,564 Fair Value Hierarchy December 31, 2021 Level 1 Level 2 Level 3 Liabilities Derivative liabilities $ - $ - $ 2,485,346 Contingent liabilities - - 11,313,000 Total $ - $ - $ 13,798,346 The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: RECONCILIATION OF LIABILITIES AT FAIR VALUE Derivative and Contingent Liabilities Balance at December 31, 2021 $ 13,798,346 Change in fair value of contingent liabilities 1,830,000 Derivative liabilities issued pursuant to Unit Purchase Agreement 1,336,218 Balance at March 31, 2022 $ 16,964,564 The Company did not have any derivative or contingent liabilities in the three months ended March 31, 2021.
Research and Development Expenses and Accruals	Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, for those individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of Duragraft, and costs related to manufacturing Duragraft for clinical trials. The Company has entered into various research and development contracts with various organizations and other companies. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be required in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense for employees and directors is recognized in the Condensed Consolidated Statements of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, we estimate the grant date fair value using our closing stock price on the date of grant. We recognize the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which our share-based awards vest.
Comparative Information	Comparative Information To conform with the current period’s financial statement presentation, the Company reclassified certain professional fees, salaries, and rent expenses related to research and development activities for the period ended March 31, 2021 into research and development expenses line item on the Condensed Consolidated Statements of Operations. Such reclassifications were not considered material and did not have any effect on the Company’s net loss for the period ended March 31, 2021.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS	Marizyme measures the following financial instruments at fair value on a recurring basis. As at March 31, 2022 and December 31, 2021, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS Fair Value Hierarchy March 31, 2022 Level 1 Level 2 Level 3 Liabilities Derivative liabilities $ $ $ 3,821,564 Contingent liabilities - - 13,143,000 Total $ - $ - $ 16,964,564
RECONCILIATION OF LIABILITIES AT FAIR VALUE	The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: RECONCILIATION OF LIABILITIES AT FAIR VALUE Derivative and Contingent Liabilities Balance at December 31, 2021 $ 13,798,346 Change in fair value of contingent liabilities 1,830,000 Derivative liabilities issued pursuant to Unit Purchase Agreement 1,336,218 Balance at March 31, 2022 $ 16,964,564

ACQUISITION (Tables)

ACQUISITION (Tables)	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION	Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid were as follows: SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION Consideration given up Common shares $ 7,774,000 Total consideration given up $ 7,774,000 Fair value of identifiable assets acquired, and liabilities assumed Net working deficit $ (613,156 ) Property, plant, and equipment 12,500 Intangible assets 6,600,000 Goodwill 1,774,656 Total identifiable assets $ 7,774,000

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2022
Leases
SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES	The following table summarizes supplemental balance sheet information related to the operating lease as of March 31, 2022 and December 31, 2021. SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES March 31, December 31, 2021 Right-of-use asset $ 1,098,059 $ 1,158,776 Operating lease liabilities, current $ 277,142 $ 277,142 Operating lease liabilities, non-current 820,917 881,634 Total operating lease liabilities $ 1,098,059 $ 1,158,776
SCHEDULE OF MATURITIES OF THE LEASE LIABILITIES	As at March 31, 2022, the maturities of the lease liabilities for the periods ending December 31 are as follows: SCHEDULE OF MATURITIES OF THE LEASE LIABILITIES 2022 207,857 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,170,233 Less: present value discount (72,174 ) Total $ 1,098,059

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE	SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE Intangible Assets March 31, 2022 December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Krillase intangible assets $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 Patents in process 122,745 - 122,745 122,745 - 122,745 DuraGraft patent 5,256,000 (673,845 ) 4,582,155 5,256,000 (572,768 ) 4,683,232 Duragraft - Distributor relationship 308,000 (51,333 ) 256,667 308,000 (43,633 ) 264,367 Duragraft IPR&D - Cyto Protectant Life Sciences 12,606,000 - 12,606,000 12,606,000 - 12,606,000 My Health Logic - Trade name 450,000 (8,840 ) 441,160 450,000 (804 ) 449,196 My Health Logic - Biotechnology 4,600,000 (74,412 ) 4,525,588 4,600,000 (6,765 ) 4,593,235 My Health Logic - Software 1,550,000 (28,416 ) 1,521,584 1,550,000 (2,583 ) 1,547,417 Total intangibles $ 53,492,745 $ (836,846 ) $ 52,655,899 $ 53,492,745 $ (626,553 ) $ 52,866,192
SCHEDULE OF GOODWILL	SCHEDULE OF GOODWILL DuraGraft My Health Logic Total Goodwill Balance, December 31, 2020 $ - $ - $ - Additions on acquisitions 5,416,000 1,774,656 7,190,656 Impairment - - - Balance, December 31, 2021 and March 31, 2022 $ 5,416,000 $ 1,774,656 $ 7,190,656
SCHEDULE OF INTANGIBLE ASSETS	The following changes to the Company’s intangible assets had taken place in the periods indicated: SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2020 $ 42,278,211 Acquired in Somah Transaction 4,022,271 Acquired in My Health Logic Transaction 6,600,000 Additions 2,775 Amortization expense (37,065 ) Balance, December 31, 2021 $ 52,866,192 Amortization expense (210,293 ) Balance, March 31, 2022 $ 52,655,899

CONVERTIBLE PROMISSORY NOTES _2

CONVERTIBLE PROMISSORY NOTES AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES	During the three months ended March 31, 2022, the Company recognized interest and accretion expense of $ 291,997 Nil SCHEDULE OF CONVERTIBLE NOTES Convertible Notes, Net of Debt Discount Balance, December 31, 2021 $ 26,065 Convertible notes issued - new securities 4,008,653 Issuance costs (271,198 ) Debt discount (3,737,455 ) Debt accretion 291,997 Balance, March 31, 2022 $ 318,062
SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT	As of March 31, 2022 and December 31, 2021, the Company had the following convertible notes, net of debt discount outstanding: SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT March 31, 2022 December 31, 2021 Convertible notes - total principal $ 11,464,692 $ 7,482,104 Unamortized issuance costs and discount (11,146,630 ) (7,456,039 ) Convertible notes, net of debt discount $ 318,062 $ 26,065

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The summary of option activity for the three months ended March 31, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of Options Weighted Average Exercise Price Weighted Average Contractual Life Total Intrinsic Value Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 Granted 1,532,500 1.51 Forfeited (1,682,500 ) 1.36 Outstanding at December 31, 2021 3,650,943 $ 1.24 8.34 $ 1,951,117 Granted/forfeited - - Outstanding at March 31, 2022 3,650,943 1.24 8.10 2,571,777 Exercisable at March 31, 2022 2,561,023 $ 1.10 7.56 $ 2,160,932
SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE	As of March 31, 2022, the Company had the following options outstanding: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number of Options Outstanding Number of Options Exercisable Weighted Average Remaining Contractual Years Intrinsic Value $ 1.01 1,985,943 1,985,943 7.18 $ 1,846,927 1.25 665,000 265,080 8.85 458,850 1.37 200,000 190,000 8.39 114,000 1.75 800,000 120,000 9.66 152,000 $ 1.24 3,650,943 2,561,023 8.10 $ 2,571,777
SCHEDULE OF WARRANTS OUTSTANDING	SCHEDULE OF WARRANTS OUTSTANDING Number Weighted Average Price December 31, 2020 3,393,651 $ 2.13 Issued pursuant to Unit Purchase Agreement 8,521,187 2.25 Issued 230,000 1.39 December 31, 2021 12,144,838 $ 2.20 Issued pursuant to Unit Purchase Agreement 4,581,319 2.25 Issued 300,000 0.01 Exercised (300,000 ) 0.01 March 31, 2022 16,726,157 $ 2.21

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ 53,948,448	$ 47,823,563
[custom:WorkingCapital-0]	2,031,884	1,268,097
Cash	$ 3,172,967	$ 4,072,339

SCHEDULE OF FAIR VALUES OF FINA

SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Contingent liabilities	$ 13,143,000	$ 11,313,000
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative Liability
Contingent liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative Liability
Contingent liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative Liability	3,821,564	2,485,346
Contingent liabilities	13,143,000	11,313,000
Total	$ 16,964,564	$ 13,798,346

RECONCILIATION OF LIABILITIES A

RECONCILIATION OF LIABILITIES AT FAIR VALUE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Change in fair value of contingent liabilities	$ 1,830,000
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Contingent liabilities beginning balance	13,798,346
Change in fair value of contingent liabilities	1,830,000
Derivative liabilities issued pursuant to Unit Purchase Agreement	1,336,218
Contingent liabilities ending balance	$ 16,964,564

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
[custom:MidrangeAverageEstimatedInterestRate]	20.60%
Liabilities, Fair Value Adjustment	$ 1,065,000
Royalty Expense	5,053,000
Liquidation preference fair market value	1,823,000
[custom:ContingentLiabilities-0]	13,143,000	$ 11,313,000
Fair Value, Inputs, Level 1 [Member]
Derivative Liability
[custom:ContingentLiabilities-0]
Derivative Instruments in Hedges, Liabilities, at Fair Value
Fair Value, Inputs, Level 2 [Member]
Derivative Liability
[custom:ContingentLiabilities-0]
Derivative Instruments in Hedges, Liabilities, at Fair Value
Fair Value, Inputs, Level 3 [Member]
Derivative Liability	3,821,564	2,485,346
[custom:ContingentLiabilities-0]	13,143,000	11,313,000
Derivative Instruments in Hedges, Liabilities, at Fair Value	16,964,564	$ 13,798,346
Scenario, Adjustment [Member]
Liabilities, Fair Value Adjustment	$ 41,000
[custom:PreTaxDiscountRatePercentage]	20.60%
Money Market Funds, at Carrying Value	$ 1,109,000
Warrants Liabilities [Member]
Increase (Decrease) in Derivative Liabilities	806,000
Fair Value Adjustment of Warrants	$ 5,158,000
Measurement Input, Risk Free Interest Rate [Member] | Warrants Liabilities [Member]
Warrants and Rights Outstanding, Measurement Input	0.0119
Measurement Input, Risk Free Interest Rate [Member] | Liquidation Preference [Member]
Expected dividend	0.0021
Measurement Input, Price Volatility [Member] | Warrants Liabilities [Member]
Warrants and Rights Outstanding, Measurement Input	0.6962
Measurement Input, Price Volatility [Member] | Liquidation Preference [Member]
Expected dividend	0.7893
Measurement Input, Expected Dividend Rate [Member] | Warrants Liabilities [Member]
Warrants and Rights Outstanding, Measurement Input	0
Measurement Input, Expected Dividend Rate [Member] | Liquidation Preference [Member]
Expected dividend	0
Measurement Input, Expected Term [Member] | Warrants Liabilities [Member]
Warrants and Rights Outstanding, Term	6 years 2 months 15 days
Measurement Input, Expected Term [Member] | Liquidation Preference [Member]
Expected years	5 years

SCHEDULE OF PRELIMINARY ALLOCAT

SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 7,190,656	$ 7,190,656
My Health Logic Inc [Member]
Business Acquisition [Line Items]
Common shares	7,774,000
Total consideration given up	7,774,000
Net working capital	(613,156)
Property, plant and equipment	12,500
Intangibles assets	6,600,000
Goodwill	1,774,656
Total identifiable assets	$ 7,774,000

ACQUISITION (Details Narrative)

ACQUISITION (Details Narrative) - USD ($)	Dec. 22, 2021	Mar. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Common stock, shares, issued		40,828,188	40,528,188
Common stock, shares, outstanding		40,828,188	40,528,188
Notes Payable		$ 204,525	$ 469,252
Unit Purchase Agreement [Member]
Business Acquisition [Line Items]
Notes Payable		278,678
My Health Logic [Member]
Business Acquisition [Line Items]
Notes Payable		$ 468,137
Debt Instrument, Interest Rate, Stated Percentage		9.00%
Interest Expense, Medium-term Notes		$ 6,085
Percentage of weighted average cost inventory		37.50%
My Health Logic [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Remaining useful life		14 years
My Health Logic [Member] | Software [Member]
Business Acquisition [Line Items]
Economic life		15 years
My Health Logic [Member] | Lab on Chip Technology [Member]
Business Acquisition [Line Items]
Remaining useful life		17 years
HL Two Holdings [Member]
Business Acquisition [Line Items]
Stock exchange acquisition common stock	$ 4,600,000
Common stock issued	230,000
Acquisition	11.35%
Common stock, shares, issued	40,528,188
Common stock, shares, outstanding	40,528,188

SCHEDULE OF RIGHT-OF-USE ASSET

SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Leases
Right-of-use asset	$ 1,098,059	$ 1,158,776
Operating lease liabilities, current	277,142	277,142
Operating lease liabilities, non-current	820,917	881,634
Total operating lease liabilities	$ 1,098,059	$ 1,158,776

SCHEDULE OF MATURITIES OF THE L

SCHEDULE OF MATURITIES OF THE LEASE LIABILITIES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Leases
2022	$ 207,857
2023	277,142
2024	277,142
2025	277,142
Thereafter	130,950
Total lease payments	1,170,233
Less: present value discount	(72,174)
Total	$ 1,098,059	$ 1,158,776

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 11, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lessee, Operating Lease, Renewal Term				5 years 6 months
Payments for Rent		$ 110,900	$ 35,600
Operating Expenses		$ 3,995,341	$ 2,884,503
Lessee, Operating Lease, Remaining Lease Term		4 years 2 months 1 day
Operating Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for Rent	$ 10,800
[custom:BaseRentPercentage]	2.50%
Operating Expenses	$ 12,000
Operating lease discount rate		3.95%

SCHEDULE OF INTANGIBLE ASSETS A

SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 53,492,745	$ 53,492,745
Accumulated amortization	(836,846)	(626,553)
Net carrying amount	52,655,899	52,866,192
Krillase Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	28,600,000	28,600,000
Accumulated amortization
Net carrying amount	28,600,000	28,600,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	122,745	122,745
Accumulated amortization
Net carrying amount	122,745	122,745
Dura Graft Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	5,256,000	5,256,000
Accumulated amortization	(673,845)	(572,768)
Net carrying amount	4,582,155	4,683,232
Duragraft Distributor Relationship [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	308,000	308,000
Accumulated amortization	(51,333)	(43,633)
Net carrying amount	256,667	264,367
Duragraft Cyto Protectant [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	12,606,000	12,606,000
Accumulated amortization
Net carrying amount	12,606,000	12,606,000
My Health Logic Trade Name [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	450,000	450,000
Accumulated amortization	(8,840)	(804)
Net carrying amount	441,160	449,196
My Health Logic Biotechnology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	4,600,000	4,600,000
Accumulated amortization	(74,412)	(6,765)
Net carrying amount	4,525,588	4,593,235
My Health Logic Software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,550,000	1,550,000
Accumulated amortization	(28,416)	(2,583)
Net carrying amount	$ 1,521,584	$ 1,547,417

SCHEDULE OF GOODWILL (Details)

SCHEDULE OF GOODWILL (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Impairment Effects on Earnings Per Share [Line Items]
Balance, December 31, 2020
Additions on acquisitions	7,190,656
Impairment
Balance, December 31, 2021 and March 31, 2022	7,190,656
DuraGraft [Member]
Impairment Effects on Earnings Per Share [Line Items]
Balance, December 31, 2020
Additions on acquisitions	5,416,000
Impairment
Balance, December 31, 2021 and March 31, 2022	5,416,000
My Health Logic [Member]
Impairment Effects on Earnings Per Share [Line Items]
Balance, December 31, 2020
Additions on acquisitions	1,774,656
Impairment
Balance, December 31, 2021 and March 31, 2022	$ 1,774,656

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 52,866,192	$ 42,278,211
Acquired in Somah Transaction		4,022,271
Acquired in My Health Logic Transaction		6,600,000
Additions		2,775
Amortization expense	(210,293)	(37,065)
Ending Balance	$ 52,655,899	$ 52,866,192

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	Sep. 12, 2018	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Acquisition of intangible assets			$ 2,775
My Health Logic Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Aggregate fair value amount		6,600,000
DuraGraft and My Health Logic [Member]
Defined Benefit Plan Disclosure [Line Items]
2023		841,172
2024		841,172
2025		841,172
2026		841,172
2027		841,172
2028 and thereafter		$ 7,121,292
Krillase Technology [Member]
Defined Benefit Plan Disclosure [Line Items]
Acquisition of intangible assets	$ 28,600,000
DuraGraft Technology [Member]
Defined Benefit Plan Disclosure [Line Items]
Acquisition of intangible assets				$ 18,170,000

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Short-Term Debt [Line Items]
Balance, December 31, 2021	$ 26,065
Balance, March 31, 2022	318,062
Convertibles Notes [Member]
Short-Term Debt [Line Items]
Balance, December 31, 2021	26,065
Convertible notes issued - new securities	4,008,653
Issuance costs	(271,198)
Debt discount	(3,737,455)
Debt accretion	291,997
Balance, March 31, 2022	$ 318,062

SCHEDULE OF CONVERTIBLE NOTES N

SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 01, 2021
Debt Disclosure [Abstract]
Convertible notes - total principal	$ 11,464,692		$ 7,482,104
Unamortized issuance costs and discount	(11,146,630)		(7,456,039)
Convertible notes, net of debt discount	$ 318,062	$ 26,065	$ 26,065

CONVERTIBLE PROMISSORY NOTES _3

CONVERTIBLE PROMISSORY NOTES AND WARRANTS (Details Narrative)

Mar. 24, 2022USD ($)$ / sharesshares

Jan. 24, 2022$ / sharesshares

Jan. 14, 2022$ / sharesshares

Dec. 21, 2021USD ($)$ / sharesshares

Dec. 02, 2021USD ($)shares

Nov. 29, 2021$ / shares

May 27, 2021$ / sharesshares

Jul. 31, 2021USD ($)shares

May 31, 2021USD ($)$ / sharesshares

Mar. 31, 2022USD ($)$ / sharesshares

Mar. 24, 2022USD ($)d$ / sharesshares

Mar. 31, 2021USD ($)

Dec. 31, 2021USD ($)

Debt Instrument [Line Items]

Proceeds from notes payable

$ 3,411,372

Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Debt Instrument, Frequency of Periodic Payment

The Convertible Notes mature in 24 months from the initial closing date and accrue 10% of simple interest per annum on the outstanding principal amount.

Debt Instrument, Convertible, Type of Equity Security

The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $1.75 per share (previously $2.25 per the September 2021 Amendment and originally $2.50 per the May Unit Purchase Agreement).

Equity financing gross amount

$ 10

$ 10

Percentage of debt instrument of conversion price

0.75

Thershold trading days | d

60

Threshold trading days | d

20

Stock price | $ / shares

$ 6

Amunt of trading volume

$ 1,000,000

Percentage of equity securities

75.00%

Conversion terms

The conversion provision was also modified to remove the requirement that an effective registration statement allow for the issuance or resale of shares of common stock into which the convertible notes may be converted in order for the conversion price of the Convertible Notes to be subject to the reduction to 75% of the price per equity security in a qualified financing.

Minimum [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Equity financing gross amount

$ 10

$ 10

New Class C Warrants [Member]

Debt Instrument [Line Items]

Percentage of warrant coverage

200.00%

Percentage of debt instrument of conversion price

0.75

Warrant, Exercise Price, Increase | $ / shares

$ 2.25

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 2.25

Warrants exercisable term

5 years

Unit Purchase Agreement [Member]

Debt Instrument [Line Items]

Sale of stock, number of shares issued in transaction | shares

3,438,572

4,000,000

29,978

Sale of stock, price per share | $ / shares

$ 1.75

$ 2.50

$ 2.50

Debt description

Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company at an initial conversion price of $1.75 and, (ii) a warrant to purchase two shares of Common Stock at an initial purchase price of $2.25 per share (the new Class C Warrant).

Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”).

Proceeds from notes payable

$ 74,945

Sale of stock amount

74,945

Issuance costs

6,745

Sale of stock, consideration received on transaction

$ 6,000,000

Unit Purchase Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Sale of stock, number of shares issued in transaction | shares

9,714,286

Sale of stock, price per share | $ / shares

$ 2.50

Debt conversion price per share | $ / shares

2.50

Unit Purchase Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Sale of stock, price per share | $ / shares

2.25

Debt conversion price per share | $ / shares

$ 2.25

Unit Purchase Agreement [Member] | Class A Warrants [Member]

Debt Instrument [Line Items]

Sale of stock amount

$ 29,978

Warrants to purchase common shares | shares

29,978

Unit Purchase Agreement [Member] | New Class C Warrants [Member]

Debt Instrument [Line Items]

Warrants to purchase common shares | shares

4,581,319

4,581,319

4,581,319

4,581,319

Exercise price of warrants or rights | $ / shares

$ 2.25

$ 2.25

$ 2.25

$ 2.25

Warrants exercisable term

5 years

5 years

5 years

Unit Purchase Program [Member]

Debt Instrument [Line Items]

Sale of stock, number of shares issued in transaction | shares

98,889

440,000

Proceeds from notes payable

$ 222,500

$ 1,100,000

Sale of stock amount

$ 1,100,000

Convertible notes payable

$ 222,500

Unit Purchase Program [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Shares issued | shares

197,778

Unit Purchase Program [Member] | Class A Warrants [Member]

Debt Instrument [Line Items]

Warrants to purchase common shares | shares

440,000

Unit Purchase Program [Member] | Class B Warrants [Member]

Debt Instrument [Line Items]

Warrants to purchase common shares | shares

440,000

December 2021 Exchange Agreement [Member]

Debt Instrument [Line Items]

Sale of stock, number of shares issued in transaction | shares

2,290,659

Shares issued | shares

2,290,659

Sale of stock, consideration received on transaction

$ 4,008,653

Investments

$ 6,000,000

Debt instrument, maturity date

Dec. 21, 2023

Exercise price of warrants or rights | $ / shares

$ 2.25

Percentage of warrant coverage

200.00%

Pro-rata Units | shares

621,087

Aggregate pro rata units | shares

832,022

Notes payable issued to settle | shares

159,245

Accounts payable issued to settle | shares

22,857

Exchange for services | shares

171,428

Fair value adjustment of warrants

$ 2,401,237

$ 4,299,649

Fair value of derivative liability

$ 1,336,218

$ 2,485,346

December 2021 Exchange Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Sale of stock, price per share | $ / shares

$ 2.25

Debt conversion price per share | $ / shares

2.25

December 2021 Exchange Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Sale of stock, price per share | $ / shares

1.75

Debt conversion price per share | $ / shares

$ 1.75

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Number of Options, Outstanding beginning Balance	3,650,943	3,800,943
Weighted Average Exercise Price, Outstanding beginning Balance	$ 1.24	$ 1.36
Weighted average contractual life term, outstanding		8 years 9 months 25 days
Number of Options, Granted	0	1,532,500
Weighted Average Exercise Price, Granted		$ 1.51
Number of Options, Forfeited		(1,682,500)
Weighted Average Exercise Price, Forfeited		$ 1.36
Number of Options, Outstanding Ending Balance	3,650,943	3,650,943
Weighted Average Exercise Price, Outstanding Ending Balance	$ 1.24	$ 1.24
Weighted average contractual life term, outstanding	8 years 1 month 6 days	8 years 4 months 2 days
Total Intrinsic Value, Ending Balance	$ 2,571,777	$ 1,951,117
Number of Options, Granted/forfeited
Weighted Average Exercise Price, Granted/forfeited
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	2,561,023
Weighted Average Exercise Price, Exercisable	$ 1.10
Weighted average contractual life term, exercisable	7 years 6 months 21 days
Total Intrinsic Value, exercisable	$ 2,160,932

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Intrinsic value	$ 2,571,777	$ 1,951,117
Exercise Price Range 1.01 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.01
Share based compensation Number of option outstanding	1,985,943
Share based compensation number of options exercisable	1,985,943
Remaining Life in Years	7 years 2 months 4 days
Intrinsic value	$ 1,846,927
Exercise Price Range 1.25 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.25
Share based compensation Number of option outstanding	665,000
Share based compensation number of options exercisable	265,080
Remaining Life in Years	8 years 10 months 6 days
Intrinsic value	$ 458,850
Exercise Price Range 1.37 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.37
Share based compensation Number of option outstanding	200,000
Share based compensation number of options exercisable	190,000
Remaining Life in Years	8 years 4 months 20 days
Intrinsic value	$ 114,000
Exercise Price Range 1.75 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.75
Share based compensation Number of option outstanding	800,000
Share based compensation number of options exercisable	120,000
Remaining Life in Years	9 years 7 months 28 days
Intrinsic value	$ 152,000
Exercise Price Range 1.24 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.24
Share based compensation Number of option outstanding	3,650,943
Share based compensation number of options exercisable	2,561,023
Remaining Life in Years	8 years 1 month 6 days
Intrinsic value	$ 2,571,777

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Begining balance	12,144,838
Weighted average exercise price, exercised		$ 1.51
Warrants outstanding, Ending balance	16,726,157	12,144,838
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Begining balance	12,144,838	3,393,651
Weighted average exercise price, outstanding, beginning balance	$ 2.20	$ 2.13
Weighted average exercise price, issued	0.01	1.39
Warrants outstanding, issued	300,000	230,000
Warrants outstanding, Exercised	(300,000)
Weighted average exercise price, exercised	$ 0.01
Warrants outstanding, Ending balance	16,726,157	12,144,838
Warrants outstanding, Ending balance	$ 2.21	$ 2.20
Warrant [Member] | Unit Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance pursuant to unit purchase agreement	4,581,319	8,521,187
Weighted average exercise price, issued	2.25	2.25

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Mar. 24, 2022	Mar. 15, 2022	Feb. 14, 2022	Jan. 26, 2022	Jan. 24, 2022	Jan. 14, 2022	May 18, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized								25,000,000		25,000,000
Preferred stock, par value								$ 0.001		$ 0.001
Preferred stock, shares issued								0		0
Preferred stock, shares outstanding								0		0
Common stock, shares authorized								75,000,000		75,000,000
Common stock, par value								$ 0.001		$ 0.001
Common stock, shares issued								40,828,188		40,528,188
Common stock, shares outstanding								40,828,188		40,528,188
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross								0		1,532,500
Gross proceeds from sale of equity								$ 5,000,000
Class of Warrant or Right, Outstanding								16,726,157		12,144,838
Share-Based Payment Arrangement, Expense								$ 716,432	$ 367,718
New Class C Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercisable term								5 years
Unit Purchase Agreement [Member] | New Class C Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price per share	$ 2.25				$ 2.25	$ 2.25
Warrants exercisable term	5 years				5 years	5 years
Warrant to purchase shares of common stock	4,581,319				4,581,319	4,581,319
Stock Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized							5,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant								1,274,057		1,274,057
Mr.Richmond [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercised								300,000
Directors Senior Officers and Consultants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures								$ 295,750
Bradely Richmond [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercised		300,000
Warrants to purchase			300,000	300,000
Warrant exercise price per share			$ 0.01	$ 0.01
Warrants exercisable term								5 years
Fair value of warrants								$ 568,677
Bradely Richmond [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants to purchase			300,000	300,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Related party transactions owned	$ 271,371		$ 1,132,634
Related party transactions, professional expenses	43,200
Related party transaction, amounts of transaction	96,744
Prepaid Royalties	339,091		339,091
Frank Maresca [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Related party transactions owned	271,371		1,132,634
Maresca [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Related party transactions, professional expenses	60,000
Related party transaction, amounts of transaction	$ 271,371		$ 271,371

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Jan. 29, 2022	Aug. 19, 2021	Jul. 13, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Loss Contingencies [Line Items]
Salary and wages				$ 915,640	$ 884,041
Issuance of stock options				0		1,532,500
Royalties percentage				10.00%
DuraGraft [Member]
Loss Contingencies [Line Items]
Sale of asset percentage				15.00%
DuraGraft [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Net proceeds from sale of asset				$ 20,000,000
UNITED STATES | First 50,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				5.00%
UNITED STATES | 50,000,001 up to 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				4.00%
UNITED STATES | Over 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				2.00%
Non-US [Member] | First 50,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				6.00%
Non-US [Member] | 50,000,001 up to 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				4.00%
Non-US [Member] | Over 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage				2.00%
July 13, 2022 [Member]
Loss Contingencies [Line Items]
Salary and wages			$ 30,000
July 13, 2021 [Member]
Loss Contingencies [Line Items]
Issuance of stock options			250,000
Shares issued, price per share			$ 1.50
Campbell [Member]
Loss Contingencies [Line Items]
Damages sought, value		$ 30,000
Harmon [Member]
Loss Contingencies [Line Items]
Damages sought, value		$ 50,000
Ms. Chandler [Member]
Loss Contingencies [Line Items]
Damages sought, value	$ 30,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jul. 02, 2022	May 11, 2022	May 01, 2022	Apr. 02, 2022	Dec. 02, 2021	Jul. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Subsequent Event [Line Items]
Base rent							$ 110,900	$ 35,600
Remaining lease term							4 years 2 months 1 day
Operating expenses							$ 3,995,341	2,884,503
Proceeds from notes payable							$ 3,411,372
Lease Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Base rent	$ 8,682		$ 3,757	$ 4,510
Base rent percentage			6.00%	2.50%
Remaining lease term			4 years 3 months 18 days
Lease expiration date			Jul. 30, 2026
Operating expenses			$ 3,344
Unit Purchase Program [Member]
Subsequent Event [Line Items]
Number of shares sold					98,889	440,000
Proceeds from notes payable					$ 222,500	$ 1,100,000
Convertible notes payable					$ 222,500
Unit Purchase Program [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued					197,778
Unit Purchase Program [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares sold		746,563
Proceeds from notes payable		$ 1,306,485
Convertible notes payable		$ 1,306,485
Unit Purchase Program [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued		1,493,126